Tanox to Buy Sunol Tissue Factor Assets
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 59 (Table of Contents)
Published: 5 May-2005
DOI: 10.3833/pdr.v2005.i59.683 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Tanox and Sunol Molecular entered into licensing agreement to acquire rights to Sunol’s tissue factor antagonist for treating inflammatory disease and cancer including tissue factor antagonist cH36, a chimeric antitissue factor monoclonal antibody for treating acute lung injury and acute respiratory distress syndrome...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS